Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2016 1
2017 1
2019 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean seong won hong (2 results)?
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.
Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q, D'Orvilliers A, Garnova E, Rafique A, Poueymirou W, Martin J, Huang T, Skokos D, Kantrowitz J, Popke J, Mohrs M, MacDonald D, Ioffe E, Olson W, Lowy I, Murphy A, Thurston G. Burova E, et al. Among authors: hong s. Mol Cancer Ther. 2017 May;16(5):861-870. doi: 10.1158/1535-7163.MCT-16-0665. Epub 2017 Mar 6. Mol Cancer Ther. 2017. PMID: 28265006
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice.
Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A, Pei J, Rafique A, Poueymirou W, Martin J, MacDonald D, Olson WC, Murphy A, Ioffe E, Thurston G, Mohrs M. Burova E, et al. Among authors: hong s. Mol Cancer Ther. 2019 Nov;18(11):2051-2062. doi: 10.1158/1535-7163.MCT-18-1376. Epub 2019 Aug 8. Mol Cancer Ther. 2019. PMID: 31395688
Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization.
Kinsella TJ, Kinsella MT, Hong S, Johnson JP, Burback B, Tosca PJ. Kinsella TJ, et al. Among authors: hong s. Cancer Chemother Pharmacol. 2008 Feb;61(2):323-34. doi: 10.1007/s00280-007-0518-4. Epub 2007 Jun 12. Cancer Chemother Pharmacol. 2008. PMID: 17562042